Background: Angiotensin-converting enzyme inhibitor-associated angioedema (ACEI-AAE) occurs in 0.1%-0.7% of patients treated with ACEIs. While previous research suggests that angioedema attacks result from increased vascular permeability, the pathogenesis is not completely understood.
INTRODUCTION Background
Angioedema (AE) is localized and self-limiting edema involving the subcutaneous tissues and submucosa, and it can be an expression of either allergic or non-allergic diseases. Angiotensin-converting enzyme inhibitor-associated AE (ACEI-AAE), a form of acquired AE without wheals [1, 2] , is a rare adverse effect related to ACEI treatment that occurs in 0.1%-0.7% of ACEI-treated patients [3] .
The pathogenesis of ACEI-AAE is not completely understood. Previous studies have demonstrated that the pharmacological inhibition of ACE leads to reduced catabolism of vasoactive mediators (e.g., bradykinin, substance P), which may result in their accumulation and a consequent increase of vascular permeability.
However, uncertainties regarding ACEI-AAE pathogenesis remain, as only a small percentage of ACEItreated patients experience AE, and the time to symptoms onset varies considerably. Therefore, predisposing factors may exist, and other mediators might contribute to the pathogenesis and/or regulation of vascular permeability in ACEI-AAE. Our group recently demonstrated an increased plasma concentration of vascular endothelial growth factors (VEGFs) and angiopoietins (Angs) [4] , and increased activity of secretory phospholipases A 2 (sPLA 2 ) [5] in patients with hereditary AE due to C1-inhibitor deficiency (C1-INH-HAE). Thus, evaluating the clinical and laboratory characteristics of vascular permeability in patients with other forms of bradykinin-mediated AE, such as ACEI-AAE, may elucidate the pathogenesis and stratification of patients treated with ACEIs who are potentially at risk of developing this adverse event.
Recently, Firinu et al. demonstrated the importance of conducting genetic investigations in patients with different forms of idiopathic AE for accurate diagnostic work-ups [6] . When clinicians encounter a recurrent form of AE with normal C1-INH levels and no specific diagnostic biomarkers, distinguishing between hereditary and acquired AE is difficult. Family history and age of onset may occasionally be informative because there are forms of AE where family history is negative, age of onset is advanced, and ACEI treatment triggers the activation of the carrier state [7] , leading to a misdiagnosis of ACEI-AAE. These issues may arise, for example, in the case of F12 mutations with incomplete penetrance, which can describe up to J Investig Allergol Clin Immunol 2020; Vol. 30 (4) © 2019 Esmon Publicidad doi: 10.18176/jiaci.0458 referred for a routine medical checkup and volunteered for the study by giving informed consent.
Technicians performing the assays were blinded to the patients' history. Blood samples from all patients were obtained at least 8 days after an AE attack (remission sample). The samples were collected via clean venipunctures and minimal stasis using 3.2% sodium citrate. After centrifugation at 2000 g for 20 min at room temperature, the plasma was divided into aliquots and stored at -80°C until tested.
Complement system
The activity of C1-INH was measured by a commercially available kit containing a specific chromogenic substrate (Technoclone GmbH, Vienna, Austria).
Determination of VEGFs and Angs
Plasma levels of angiogenic and lymphangiogenic mediators were measured using commercially available ELISA kits for VEGF-A, VEGF-C, Ang1, and Ang2 (R&D System, Minneapolis, USA) according to the manufacturer's instructions. The ELISA sensitivity was 31.1-2,000 pg/ml for VEGF-A, 62-4,000 pg/ml for VEGF-C, 156.25-10,000 pg/ml for Ang1, and 31.1-4,000 pg/ml for Ang2.
Functional test of sPLA2
The activity of sPLA 2 in the plasma of ACEI-AAE patients, healthy controls and subjects treated with ACEIs without angioedema was measured by EnzChek ® phospholipase A 2 assay (Life Technologies, Carlsbad, California, USA). Briefly, an sPLA 2 substrate cocktail consisting of 7-hydroxycoumarinyl-arachidonate (0.3 mM), 7-hydroxycoumarinyl-linolenate (0.3 mM), hydroxycoumarinyl-6 heptenoate (0.3 mM), dioleoylphosphatidylcholine (DOPC) (10 mM), and dioleoylphosphatidylglycerol (DOPG) (10 mM) was prepared in ethanol. Liposomes were formed by gradually adding 77 µl of substrate/lipid cocktail to 10 ml of PLA 2 buffer (50 mMTris-HCl, 100 mMNaCl, and 1 mM CaCl 2 ) while stirring rapidly over 1 min with a magnetic stirrer. Fluorescence (excitation at 360 nm and emission at 460 nm) was measured, and the specific activity (relative fluorescent units/ml) was calculated for each sample. Fifty-microliter aliquots of plasma from ACEI-AAE patients, subjects treated with ACEIs without angioedema, and healthy controls J Investig Allergol Clin Immunol 2020; Vol. 30 (4) © 2019 Esmon Publicidad doi: 10.18176/jiaci.0458 were added to 96-well plates, and sPLA 2 activity in the samples was measured by adding 50 µl of substrate cocktail.
Genetic screening
Direct DNA sequencing was conducted with the Big Dye® Terminator Cycle Sequencing Kit 3.1 (Applied Biosystems, Forster City, CA USA). The obtained sequences were compared with consensus sequences from specific databases (Ensembl 2011).
Statistical analysis
Collected data were processed using statistical software (GraphPadPrism 5, GraphPad Software, San Diego, CA, USA), and were tested for normality using the D'Agostino-Pearson normality test. Data with a normal distribution determined at a significance level of 0.05 were subjected to parametric tests. Non-parametric tests were used for non-normally distributed data. Two-tailed t-tests were performed for independent samples, and two-tailed Mann-Whitney tests were performed as indicated in the figure legends. The correlation between two variables was assessed by the Pearson or Spearman test and reported as a coefficient of correlation (r). A P value ≤ 0.05 was considered statistically significant.
RESULTS

Clinical characteristics of the participants
A total of 51 Caucasian patients with ACEI-AAE were included in this study. As controls, 86 healthy subjects and 20 ACEI-treated subjects without AE were enrolled. Table I summarizes Among the ACEI-AAE patients, ACEI prescriptions included ramipril (27.5%), enalapril (23.5%), lisinopril (17.6%), zofenopril (13.7%), perindopril (11.8%), fosinopril (3.9%), and delapril (2%). In ACEI-treated patients without AE, ACEI prescriptions included ramipril (70%), lisinopril (15%), enalapril (10%), and zofenopril (5%).
Measuring from the initiation of the ACEI therapy, the median number of total AE attacks per patient was 3 (range 1-180). An average AE attack frequency per year could not be estimated as 31.4% of patients discontinued ACEI after the first or second episode.
The distribution of attack frequency by site was as follows: lips (74.5%), tongue (51.9%), face (41.2%), upper airways (29.5%), skin (17.6%), genitals (5.9%), and abdomen (3.9%). Values are expressed as noncumulative percentages, meaning patients may have exhibited attacks involving multiple locations simultaneously.
The average AE attack duration was 24 hours (range 3-168 hours). The attacks lasted ≥24 hours in 56.8% of patients, 12-23 hours in 35.4%, and less than 12 hours in 7.8% of patients.
After diagnosis, the patients received follow-up assessments for up to 12 years, with a minimum follow-up time of 6 months. Ninety-eight percent of patients suspended ACEI use, whereas 2% (1 patient) did not discontinue the drug and their AE attacks persisted. The control group with ACEI-treated subjects without AE was treated with ACEI for a minimum time of 6 months to 20 years.
After discontinuation of ACEI therapy, 68% (34 patients) no longer experienced AE. Among these patients, 41.2% took ARBs without presenting AE. Only 32% (16 patients) continued to have AE episodes despite the suspension of ACEI use, as reported in Figure 1 .
For antihypertensive replacement therapy, we observed that 44% (22/50) switched to ARBs, while 56% of patients (28/50) started other antihypertensive drugs or discontinued antihypertensive therapy (36% to calcium antagonists, 14% to no therapy, and 8% to beta-blockers, alpha-blockers, or diuretics). We found that 9/22 patients developed AE during ARBs treatment but for 2 patients AE was not related to ARBs (1 with spontaneous resolution despite the continuation of ARBs; 1 with persistent AE after ARBs J Investig Allergol Clin Immunol 2020; Vol. 30 (4) © 2019 Esmon Publicidad doi: 10.18176/jiaci.0458 discontinuation). Ultimately, ARBs-induced AE were confirmed in 31.8% of patients (7/22) . The prevalence of AE in patients treated with other antihypertensive drugs was 28.6% (8/28).
Among the patients with persistent attacks, the attacks recurred in 50% of patients treated with either ramipril, perindopril, or fosinopril, 28.5% of patients treated with zofenopril, 11% of patients treated with lisinopril, and 8.3% of patients treated with enalapril.
Prior to the diagnosis of ACEI-AAE, all patients received corticosteroids and/or antihistamines during acute attacks, and displayed no improvement of symptoms. Three patients received intramuscular adrenaline as adjunctive therapy but did not report positive effects on the duration of the episodes, or side effects related to the drug. One patient received icatibant as add-on therapy but did not show a significant reduction in attack duration. In contrast, the Ang1 and Ang2 plasma levels of patients with ACEI-AAE were not altered compared with those of the healthy controls or ACEI-treated subjects without AE ( Figure 2C -2D).
Laboratory parameters of the population
The sPLA 2 enzymatic activity was approximately 3 times higher in patients with ACEI-AAE than in healthy controls or ACEI-treated subjects without AE. The median enzymatic activities of the groups were 3.9 (2.4-5.7), 1.27 (0.6-1.8), and 1.86 (1.05-2.5) U/ml, respectively ( Figure 2E ).
According to our data, some ACEIs led to AE more frequently than others. Therefore, we divided the ACEI-AAE patients into groups based on their ACEI therapies and evaluated the concentrations of VEGF-A, concentrations of VEGF-C, and sPLA 2 enzymatic activity within each group. Patients treated with enalapril, ramipril, or zofenopril had higher levels of VEGF-A, VEGF-C, and sPLA 2 than the controls (Figure 3 ). J Investig Allergol Clin Immunol 2020; Vol. 30 (4) © 2019 Esmon Publicidad doi: 10.18176/jiaci.0458
We also investigated possible correlations between laboratory parameters and clinical features of AE attacks. We found no significant relationship between plasma concentrations of VEGF-A and VEGF-C, activity of sPLA 2 , and time between the onset of therapy and symptoms onset. Furthermore, no correlation was observed between the laboratory parameters and age of symptoms onset, duration of episodes, or number of sites involved.
To determine whether ACEI therapy influenced the patients' plasma levels of VEGF-A and VEGF-C and the activity of sPLA 2 , we assessed the relationship between the laboratory parameters and the duration from plasma draw to ACEI therapy discontinuation. However, the results did not reveal a significant correlation between this clinical feature and variations in the laboratory parameters ( Figure 4) .
In further analysis, the patients were divided into three groups according to their persistence of AE attacks after ACEI discontinuation. The groups included patients with persistence of the attacks after ACEI discontinuation, patients who experienced attacks within 1 year after ACEI discontinuation, and patients with a resolution of symptoms following therapy suspension (no attacks). We then analyzed the laboratory parameters of the three patient groups. Figure 5 shows that the plasma concentrations of VEGF-A and VEGF-C, and the activity of sPLA 2 did not vary in the three groups analyzed.
Genetic characteristics of the population
We performed a genetic analysis of SERPING1 gene, ANGPT1 gene, ap.Thr309Lys missense mutation in F12 gene, and a p.Lys330Glu missense mutation in PLG gene in 33 patients, including 5 patients whose AE episodes persisted after ACEI suspension. No mutations were detected. Here, we report the clinical characteristics of a Caucasian patient cohort and highlight some correlations that only partially confirm previous data regarding the possible roles of the female sex, smoking, and age over 65 years as risk factors associated with ACEI-AAE. Our results differ from the literature in terms of correlations with sex, as most of our patients were male [13] [14] [15] . Furthermore, there was a nearly uniform distribution between smokers and non-smokers in our study (45% vs 55%). A correlation between ACEI-AAE and age was present but not strong, although approximately 50% of our patients were ≥ 65 years of age.
DISCUSSION
Diabetes is commonly reported in the literature as a protective factor, which is congruent with our results (14% patients with diabetes vs. 86% without), supporting the role of DPP-4 as an important enzyme in bradykinin (BK) catabolism [16] [17] [18] . A more controversial topic is the correlation between IgE-mediated diseases and ACEI-AAE. While some studies consider the history of atopy and drug allergy as risk factors for ACEI-AAE [13, 14] , others do not find a significant relationship between the two mechanisms [15] . In our study's population, the history of atopy and drug allergy did not appear to be risk factors for ACEI-AAE as they were only present in a small percentage of patients (23.5% and 15.7%, respectively). However, they were associated with an increased frequency of developing histamine-mediated symptoms, such as pruritus and rash, during episodes of AE. Of the 8 patients suffering from drug allergy in our cohort, 50% exhibited associated symptoms during AE episodes, as if the tendency of these patients to develop histamine-mediated drug reactions conferred susceptibility to the release of histamine during episodes of BK-mediated AE. Some authors propose that an initial histamine release might trigger BK-mediated AE attacks, although this hypothesis is yet to be supported by sufficient evidence [19, 20] . However, there is evidence to support the notion that classic antiallergic drugs such as antihistamines and corticosteroids are not effective in ACEI-AAE treatment, and the histamine contribution is present but not significant.
The time frame for ACEI-AAE presentation varies widely. Data from our cohort show that ACEI-AAE may develop at any time after the initiation of ACEI therapy, from 3 days to 20 years after the first administration, which agrees with the trend demonstrated by various studies [21, 22] . J Investig Allergol Clin Immunol 2020; Vol. 30 (4) © 2019 Esmon Publicidad doi: 10.18176/jiaci.0458
The ACEI most correlated with the onset of AE in our cohort was ramipril (27.5%), followed by enalapril (23.5%) and lisinopril (17.6%). Although in Italy these drugs, especially enalapril, are among the most prescribed in their class [23] , a potentially higher risk of developing ACEI-AAE in patients taking such drugs compared with that in patients taking other ACEIs cannot be excluded. This increased risk may be partially explained by the prolonged half-life of enalapril (11 hours), ramipril (15 hours), and lisinopril (12 hours), along with the greater potency expressed as IC50 (concentration required to inhibit 50% of the enzymatic activity) of these ACEIs compared to that of others [24] . Montoro et al. showed that the use of enalapril was associated with an increased risk of developing ACEI-AAE compared with the use of other ACEIs [25] .
Other studies showed a greater percentage of ACEI-AAE occurrence in patients treated with lisinopril [22, 26, 27] . As a possible explanation, the authors report that lisinopril was the most prescribed drug in their patient population, although lisinopril is also part of the triad of ACEIs with longer half-life and greater potency.
After discontinuation from ACEIs, 68% of our cohort (34 patients) no longer experienced AE attacks, while 16 patients (32%) had AE recurrences. These data, in accordance with a study by Cicardi et al. [28] , suggest that discontinuation from ACEI may not be sufficient to prevent symptom recurrence in a considerable percentage of patients.
In our study, there were no significant differences in AE incidence observed between the group treated with ARBs (31.8%) and the groups treated with other antihypertensive drugs (28.6%). The difference between two groups were not significant considering that ARBs as replacement therapy were the most prescribed drugs compared to single antihypertensive, and that among 6 patients with persistent AE after the first year of ACEI discontinuation, only 2 patients were treated with ARBs (1 with ARBs-induced AE and no ARBs discontinuation, 1 with persistent AE after ARBs discontinuation) while 4 patients were treated with other antihypertensive drugs (Figure 1 ).
Although our sample size was limited, the disease of interest is a rare pathology, and the data from our population contribute to the understanding of ACEI-AAE. Our study intended to combine real-world data J Investig Allergol Clin Immunol 2020; Vol. 30 (4) © 2019 Esmon Publicidad doi: 10.18176/jiaci.0458 with new laboratory findings to investigate the pathogenesis of ACEI-AAE, even in relation to the presence of hypertension, a condition with physiopathological processes that also depend on endothelial dysfunction.
The interaction between VEGFs and sPLA 2 in the regulation of vascular permeability has been demonstrated both in vivo and in vitro [29, 30] . Recently, our group demonstrated that patients with C1-INH-AAE had elevated plasma levels of VEGFs, Angs, and sPLA 2 , particularly those of the IIA group (hGIIA), in the periods without AE attacks [4, 5] .
Similarly, in this study, we aimed to test the same hypothesis on a population of patients suffering from AE who were not yet investigated. We observed a higher plasma concentration of VEGF-A and VEGF-C and greater sPLA 2 enzymatic activity in patients with ACEI-AAE in remission compared to that in healthy controls and ACEI-treated patients without AE (Figure 2A , 2B, 2E). As shown above, the increase in VEGF-A and VEGF-C plasma levels in ACEI-AAE group did not depend on drug therapy since the discontinuation of ACEI did not affect the plasma concentration ( Figure 4 ). Therefore, we hypothesized in these patients a substrate of increased vascular permeability at baseline due to the increased plasma levels of VEGF-A and VEGF-C. This state, added to ACEI therapy, could contribute to increasing the probability of developing AE compared to patients treated with ACEI but with lower VEGFs levels. The possible origin of the increased plasma levels of VEGF-A and VEGF-C at baseline remains to be clarified.
No differences in the levels of Angs were found. This could be explained by the action of antihypertensive treatment in reducing circulating levels of Ang in hypertensive patients receiving drug therapy [31, 32] .
One remarkable finding of the study was the correlation between VEGF-A, VEGF-C, and sPLA 2 levels and different types of ACEI. The highest levels of these proteins were found in patients treated with ramipril, enalapril, or zofenopril. For ramipril and enalapril, this could be associated with the aforementioned greater percentage of prescriptions and prolonged half-life. However, there are some peculiarities regarding zofenopril that should be emphasized. First, its molecular structure contains a sulfhydryl group, and its activity induces increases in nitrogen monoxide (NO) and the reduction of endothelial adhesion patients treated with zofenopril were males.
To our knowledge, this is the first study that conducted genetic analyses of ACEI-AAE patients to investigate cases of misdiagnosed hereditary AE. In the last few years, multiple studies have shown newly discovered forms of hereditary AE with incomplete penetrance and variable clinical presentations that may interfere with accurate diagnoses [8] [9] [10] [11] [12] . In our study, genetic screening did not reveal any diagnostic errors. All patients classified as ACEI-AAE in our cohort were actually affected by the acquired form of AE. Cases initially classified as ACEI-AAE but later revealed as the inherited form are very rare, and considering the economic burden of the genetic analysis procedure, we assert that genetic screening is not necessary for patients with a history suggestive of ACEI-AAE.
The study is limited by its small ACEI-AAE patient population (51 patients) and the low number of patients subjected to laboratory evaluations (43 patients). However, gathering a large sample population for this type of investigation is difficult because ACEI-AAE is a rare condition.
In conclusion, our results demonstrate high basal levels of VEGF-A, VEGF-C, and sPLA 2 in ACEI-AAE patients, suggesting a basal predisposition to vasopermeability in ACEI-AAE patients that could play a role in the development of an AE attack, as ACEIs lead to an increase in bradykinin levels due to reduced catabolism.
However, no correlations between plasma levels of VEGF-A and VEGF-C, sPLA 2 activity, and clinical features were observed. 
